BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Saturday, December 13, 2025
See today's BioWorld
Home
» Cephalon Rejects Valeant's Hostile $5.7B Takeover Bid
To read the full story,
subscribe
or
sign in
.
Cephalon Rejects Valeant's Hostile $5.7B Takeover Bid
April 6, 2011
It took Cephalon Inc. less than a week to decide that Valeant Pharmaceutical International Inc.'s unsolicited offer to buy the biotech was undervalued.
BioWorld
